European Biosimilar Approval Updates: Adalimumab, Pegfilgrastim

Published date27 September 2018
Law FirmGoodwin
Subject MatterEU,Biosimilars,Mylan Pharmaceuticals,Pharmaceutical Industry,European Medicines Agency (EMA),Marketing Authorization Application,Coherus

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT